Prevalence and Clinical Associations of Myositis Antibodies in a Large Cohort of Interstitial Lung Diseases

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2022 Nov 3

PMID 36327336

Authors

Sofia A Moll

Mark G J P Platenburg

Anouk C M Platteel

Adriane D M Vorselaars

Montse Janssen Bonas

Raisa Kraaijvanger

Claudia Roodenburg-Benschop

Bob Meek

Coline H M van Moorsel

Jan C Grutters

Affiliations

Soon will be listed here.

Abstract

Background: Serologic testing for autoantibodies is recommended in interstitial lung diseases (ILDs), as connective tissue diseases (CTDs) are an important secondary cause. Myositis antibodies are associated with CTD-ILD, but clinical associations with other ILDs are unclear. In this study, associations of myositis antibodies in various ILDs were evaluated.

Methods: 1463 ILD patients and 116 healthy subjects were screened for myositis antibodies with a line-blot assay on serum available at time of diagnosis. Additionally, bronchoalveolar lavage fluid (BALf) was analysed.

Results: A total of 394 patients demonstrated reactivity to at least one antibody, including anti-Ro52 (36.0%), anti-Mi-2β (17.3%) and anti-Jo-1 (10.9%). Anti-Jo-1 (OR 6.4; p<0.100) and anti-Ro52 (OR 6.0; p<0.001) were associated with CTD-ILD. Interestingly, anti-Mi-2β was associated with idiopathic pulmonary fibrosis (IPF; OR 5.3; p = 0.001) and hypersensitivity pneumonitis (HP; OR 5.9; p<0.001). Furthermore, anti-Mi-2β was strongly associated with a histological usual interstitial pneumonia (UIP) pattern (OR 6.5; p < 0.001). Moreover, anti-Mi-2β reactivity was identified in BALf and correlated with serum anti-Mi-2β (r = 0.64; p = 0.002). No differences were found in survival rates between ILD patients with and without serum Mi-2β reactivity (hazard ratio 0.835; 95% CI 0.442-1.575; p = 0.577).

Conclusion: In conclusion, novel associations of antibody Mi-2β with fibrotic ILD were found. Furthermore, serum anti-Mi-2β was associated with a histological UIP pattern and presence of anti-Mi-2β in BALf. Possibly, anti-Mi-2β could be implemented as a future diagnostic biomarker for fibrotic ILD.

Citing Articles

Prognostic value of myositis-specific antibodies in patients with idiopathic interstitial pneumonia.

Wakabayashi H, Iwasaki K, Murakami Y, Takashima K, Kaneko K, Matsuzawa Y BMC Pulm Med. 2024; 24(1):503.

PMID: 39390459 PMC: 11468076. DOI: 10.1186/s12890-024-03326-w.

High Prevalence of Myositis-Specific and Associated Antibodies in Patients with Pulmonary Hypertension.

Tobal R, Potjewijd J, van Doorn D, van Empel V, Damoiseaux J, van Paassen P Diagnostics (Basel). 2024; 14(14).

PMID: 39061608 PMC: 11276054. DOI: 10.3390/diagnostics14141471.

Anti-Mi-2 antibody-positive lung cancer-associated polymyositis.

Shimoda M, Tanaka Y, Taniguchi A, Morimoto K, Yoshimori K, Ohta K Int Cancer Conf J. 2023; 12(3):173-176.

PMID: 37251005 PMC: 10212843. DOI: 10.1007/s13691-023-00601-1.

References

Nakashima R . Clinical significance of myositis-specific autoantibodies. Immunol Med. 2019; 41(3):103-112. DOI: 10.1080/25785826.2018.1531188. View

McDonough J, Ahangari F, Li Q, Jain S, Verleden S, Herazo-Maya J . Transcriptional regulatory model of fibrosis progression in the human lung. JCI Insight. 2019; 4(22). PMC: 6948862. DOI: 10.1172/jci.insight.131597. View

Handa T, Nagai S, Kawabata D, Nagao T, Takemura M, Kitaichi M . Long-term clinical course of a patient with anti PL-12 antibody accompanied by interstitial pneumonia and severe pulmonary hypertension. Intern Med. 2005; 44(4):319-25. DOI: 10.2169/internalmedicine.44.319. View

Xie M, Zou R, Li Y, Liu Y, Chen L, Liu X . [Clinical value of myositis antibodies in patients with connective tissue disease-associated interstitial lung diseases]. Zhonghua Jie He He Hu Xi Za Zhi. 2019; 42(10):765-770. DOI: 10.3760/cma.j.issn.1001-0939.2019.10.010. View

Platteel A, Wevers B, Lim J, Bakker J, Bontkes H, Curvers J . Frequencies and clinical associations of myositis-related antibodies in The Netherlands: A one-year survey of all Dutch patients. J Transl Autoimmun. 2020; 2:100013. PMC: 7388388. DOI: 10.1016/j.jtauto.2019.100013. View

Hinz B, Phan S, Thannickal V, Galli A, Bochaton-Piallat M, Gabbiani G . The myofibroblast: one function, multiple origins. Am J Pathol. 2007; 170(6):1807-16. PMC: 1899462. DOI: 10.2353/ajpath.2007.070112. View

Fidler L, Doubelt I, Kandel S, Fisher J, Mittoo S, Shapera S . Screening for Myositis Antibodies in Idiopathic Interstitial Lung Disease. Lung. 2019; 197(3):277-284. DOI: 10.1007/s00408-019-00212-9. View

Casciola-Rosen L, Nagaraju K, Plotz P, Wang K, Levine S, Gabrielson E . Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med. 2005; 201(4):591-601. PMC: 2213068. DOI: 10.1084/jem.20041367. View

Lhote R, Grenier P, Haroche J, Miyara M, Boussouar S, Mathian A . Characterization of Interstitial Lung Disease Associated With Anti-Ribonucleoprotein Antibodies. J Clin Rheumatol. 2019; 26(8):327-333. DOI: 10.1097/RHU.0000000000001127. View

10.

Mammen A, Casciola-Rosen L, Hall J, Christopher-Stine L, Corse A, Rosen A . Expression of the dermatomyositis autoantigen Mi-2 in regenerating muscle. Arthritis Rheum. 2009; 60(12):3784-93. PMC: 2828900. DOI: 10.1002/art.24977. View

11.

Papiris S, Kagouridis K, Bouros D . Serologic evaluation in idiopathic interstitial pneumonias. Curr Opin Pulm Med. 2012; 18(5):433-40. DOI: 10.1097/MCP.0b013e3283560840. View

12.

Williams C, Naito T, Gomez-Del Arco P, Seavitt J, Cashman S, De Souza B . The chromatin remodeler Mi-2beta is required for CD4 expression and T cell development. Immunity. 2004; 20(6):719-33. DOI: 10.1016/j.immuni.2004.05.005. View

13.

Marguerie C, Bunn C, Beynon H, Bernstein R, Hughes J, So A . Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med. 1990; 77(282):1019-38. DOI: 10.1093/qjmed/77.1.1019. View

14.

Bahmer T, Romagnoli M, Girelli F, Claussen M, Rabe K . The use of auto-antibody testing in the evaluation of interstitial lung disease (ILD)--A practical approach for the pulmonologist. Respir Med. 2016; 113:80-92. DOI: 10.1016/j.rmed.2016.01.019. View

15.

Hiepe F, Dorner T . [Autoantibodies and antibody-secreting cells]. Z Rheumatol. 2005; 64(6):389-95. DOI: 10.1007/s00393-005-0767-8. View

16.

Strange C, Highland K . Interstitial lung disease in the patient who has connective tissue disease. Clin Chest Med. 2004; 25(3):549-59, vii. DOI: 10.1016/j.ccm.2004.05.009. View

17.

Palmucci S, Roccasalva F, Puglisi S, Torrisi S, Vindigni V, Mauro L . Clinical and radiological features of idiopathic interstitial pneumonias (IIPs): a pictorial review. Insights Imaging. 2014; 5(3):347-64. PMC: 4035488. DOI: 10.1007/s13244-014-0335-3. View

18.

Gomez-Del Arco P, Perdiguero E, Yunes-Leites P, Acin-Perez R, Zeini M, Garcia-Gomez A . The Chromatin Remodeling Complex Chd4/NuRD Controls Striated Muscle Identity and Metabolic Homeostasis. Cell Metab. 2016; 23(5):881-92. DOI: 10.1016/j.cmet.2016.04.008. View

19.

Luzina I, Salcedo M, Rojas-Pena M, Wyman A, Galvin J, Sachdeva A . Transcriptomic evidence of immune activation in macroscopically normal-appearing and scarred lung tissues in idiopathic pulmonary fibrosis. Cell Immunol. 2018; 325:1-13. PMC: 5826809. DOI: 10.1016/j.cellimm.2018.01.002. View

20.

Saketkoo L, Ascherman D, Cottin V, Christopher-Stine L, Danoff S, Oddis C . Interstitial Lung Disease in Idiopathic Inflammatory Myopathy. Curr Rheumatol Rev. 2011; 6(2):108-119. PMC: 3092635. DOI: 10.2174/157339710791330740. View